Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2236 to 2250 of 8213 results

  1. Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years [TSID11805]

    Topic prioritisation

  2. TVB-009 (denosumab biosimilar) for treating postmenopausal osteoporosis in people aged 60 to 90 [TSID11807]

    Topic prioritisation

  3. Paclitaxel + XR17 (Paclical) with carboplatin for ovarian cancer [TSID5462]

    Topic prioritisation

  4. Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TSID10085]

    Topic prioritisation

  5. Glatiramer acetate depot for multiple sclerosis [TSID10620]

    Topic prioritisation

  6. Emtricitabine/tenofovir alafenamide for human immunodeficiency virus type-1 infection [TSID10723]

    Topic prioritisation

  7. Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TSID10722]

    Topic prioritisation

  8. Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 [TSID10766]

    Topic prioritisation

  9. Dupilumab for children with severe atopic dermatitis [TSID10434]

    Topic prioritisation

  10. CT-P43 (ustekinumab biosimilar) for treating moderate to severe plaque psoriasis [TSID11773]

    Topic prioritisation

  11. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 [TSID11778]

    Topic prioritisation

  12. Riluzole oral film for treating amyotrophic lateral sclerosis [TSID11779]

    Topic prioritisation

  13. Suspected cancer update

    In development Reference number: GID-QS10176 Expected publication date: TBC

  14. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development Reference number: GID-TA11137 Expected publication date: TBC